Pakistan · Delayed Price · Currency is PKR Liven Pharma Statistics
Total Valuation
Liven Pharma has a market cap or net worth of PKR 3.56 billion. The enterprise value is 3.41 billion.
| Market Cap | 3.56B |
| Enterprise Value | 3.41B |
Important Dates
The last earnings date was Friday, October 2, 2026.
| Earnings Date | Oct 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Liven Pharma has 113.04 million shares outstanding. The number of shares has increased by 35.87% in one year.
| Current Share Class | 113.04M |
| Shares Outstanding | 113.04M |
| Shares Change (YoY) | +35.87% |
| Shares Change (QoQ) | +14.76% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.13% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.96 |
| PB Ratio | 3.65 |
| P/TBV Ratio | 3.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 399.93 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.63 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.01 |
Financial Efficiency
Return on equity (ROE) is -3.85% and return on invested capital (ROIC) is -10.03%.
| Return on Equity (ROE) | -3.85% |
| Return on Assets (ROA) | -4.66% |
| Return on Invested Capital (ROIC) | -10.03% |
| Return on Capital Employed (ROCE) | -6.87% |
| Weighted Average Cost of Capital (WACC) | 2.83% |
| Revenue Per Employee | 2.71M |
| Profits Per Employee | -798,428 |
| Employee Count | 39 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | -35.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.22% in the last 52 weeks. The beta is -0.26, so Liven Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | -50.22% |
| 50-Day Moving Average | 32.54 |
| 200-Day Moving Average | 38.34 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 47,378 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Liven Pharma had revenue of PKR 105.81 million and -31.14 million in losses. Loss per share was -0.28.
| Revenue | 105.81M |
| Gross Profit | -10.73M |
| Operating Income | -75.93M |
| Pretax Income | -66.32M |
| Net Income | -31.14M |
| EBITDA | -46.51M |
| EBIT | -75.93M |
| Loss Per Share | -0.28 |
Balance Sheet
The company has 181.55 million in cash and 33.44 million in debt, with a net cash position of 148.11 million or 1.31 per share.
| Cash & Cash Equivalents | 181.55M |
| Total Debt | 33.44M |
| Net Cash | 148.11M |
| Net Cash Per Share | 1.31 |
| Equity (Book Value) | 985.46M |
| Book Value Per Share | 8.72 |
| Working Capital | 181.81M |
Cash Flow
In the last 12 months, operating cash flow was 8.99 million and capital expenditures -29.66 million, giving a free cash flow of -20.68 million.
| Operating Cash Flow | 8.99M |
| Capital Expenditures | -29.66M |
| Depreciation & Amortization | 29.42M |
| Net Borrowing | -4.11M |
| Free Cash Flow | -20.68M |
| FCF Per Share | -0.18 |
Margins
Gross margin is -10.14%, with operating and profit margins of -71.76% and -29.43%.
| Gross Margin | -10.14% |
| Operating Margin | -71.76% |
| Pretax Margin | -62.68% |
| Profit Margin | -29.43% |
| EBITDA Margin | -43.96% |
| EBIT Margin | -71.76% |
| FCF Margin | n/a |
Dividends & Yields
Liven Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -35.87% |
| Shareholder Yield | -35.87% |
| Earnings Yield | -0.87% |
| FCF Yield | -0.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Liven Pharma has an Altman Z-Score of 13.27 and a Piotroski F-Score of 4.
| Altman Z-Score | 13.27 |
| Piotroski F-Score | 4 |